Piramal Pharma Limited FII & DII Activity

FII Net (₹ Cr)

+871.83Buy 16,834.53Sell 15,962.7

DII Net (₹ Cr)

+643.35Buy 17,240.9Sell 16,597.55

FII F&O Net (contracts)

+643395Index + stock futures

5-Day Flow Trend

Date	FII Net (₹ Cr)	DII Net (₹ Cr)
2026-10-28	+871.83	+643.35
2026-10-27	−1462.49	+2609.57
2026-10-26	−1462.49	+2609.57
2026-10-23	+887.65	+3235.36
2026-10-22	−3458.70	+2891.32

AI AnalysisGenerated daily after market close · AI-powered

Today's Institutional Flow

Today's cash flows show foreign institutional investors (FII) adding a net ₹871.83 cr to equities, while domestic institutional investors (DII) contribute a net ₹643.35 cr, indicating a combined inflow of over ₹1.5 trillion and underscores the continued confidence in the company's pipeline and recent regulatory approvals. The FII cash injection markedly exceeds the DII contribution, reflecting a stronger appetite from overseas money managers for risk‑on positions amid a relatively stable macro backdrop, as investors seek exposure to emerging market growth prospects. Both investor classes remain net buyers despite a modest withdrawal trend observed in the broader market index yesterday.

Trend vs 5-Day Average

Today's aggregate inflow contrasts sharply with the FII five‑day average of a ₹894.74 cr outflow, underscoring a reversal of recent foreign selling pressure and aligns with a broader rally in export‑linked equities. Conversely, DII activity continues to outpace its five‑day average of ₹2,592.03 cr, reinforcing a persistent domestic buying bias in the market.

F&O Positioning Data

FII futures‑and‑options (F&O) positions register a net long of ₹643,395 cr, indicating a strong directional bet on equity upside ahead of upcoming earnings season expectations. The index futures long‑short ratio stands at 1.2, suggesting that long contracts outweigh shorts by roughly twenty percent, while short positions remain limited, reflecting cautious risk management.

Healthcare Sector Flow

In the healthcare space, both FII and DII flows have turned positive over the past week, providing sectoral support to pharma stocks.

Market-wide FII/DII data — same for all F&O stocks. Date: 2026-10-28

Same Sector

ALKEMAlkem Laboratories LimitedNeutral APOLLOHOSPApollo Hospitals Enterprise LimitedNeutral AUROPHARMAAurobindo Pharma LimitedNeutral BIOCONBiocon LimitedNeutral CIPLACipla LimitedNeutral

Frequently Asked Questions

What is FII net buying/selling in Piramal Pharma Limited today?

FII (Foreign Institutional Investor) net flow in the Indian cash market today is ₹871.83 Cr (net buying) as of 2026-10-28. This market-wide figure applies to all F&O stocks including Piramal Pharma Limited.

What is DII activity in Piramal Pharma Limited today?

DII (Domestic Institutional Investors — mutual funds, insurance companies) net flow is ₹643.35 Cr (net buying) today. DIIs often act as a counterbalancing force to FII flows — on days when FIIs sell, DIIs typically provide support.

What is FII F&O net for Piramal Pharma Limited today?

FII net F&O position (index + stock futures combined) is +6,43,395 contracts as of the latest participant OI data. A positive number means FIIs are net long in futures; negative means net short.

Were there any block deals in Piramal Pharma Limited?

Block deal data for Piramal Pharma Limited is tracked daily from NSE's block deal window. On days with activity, the deal value in ₹ Crore is shown on this page.

How does FII/DII data affect Piramal Pharma Limited stock price?

FII and DII flows are market-wide data — all F&O stocks including Piramal Pharma Limited are influenced. When FIIs buy heavily (positive net), it typically supports the broader market. When FII F&O net is strongly positive (long futures), it signals institutional conviction in an uptrend. Combined with Piramal Pharma Limited's individual OI buildup type, this provides a directional framework.